ArticleFrontiers in pharmacology2022
Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development of a real-world, therapeutic drug monitoring-informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections.International journal of clinical pharmacy · 2026Article
- Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy.Frontiers in pharmacology · 2025Article
- Machine learning-based prediction model for teicoplanin plasma concentrations in adults with liver disease using real-world data.Frontiers in pharmacology · 2025Article
- Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China.BMC geriatrics · 2024Observational
- Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation.Pharmaceutics · 2024Article
- Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.Drug design, development and therapy · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.